Skip to main content

Haemostasis

0
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 4 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
5 programs
No treatment givenN/A1 trial
clopidogrelPHASE_11 trial
eptacog alfaPHASE_11 trial
warfarinPHASE_11 trial
ConcizumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT02568202Completed449Est. Nov 2015
NCT01603342Completed18Est. Jan 2008
NCT01561950Terminated91Est. Jan 2009
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskConcizumab
Novo Nordiskeptacog alfa
Novo Nordiskclopidogrel
Novo Nordiskwarfarin
Novo NordiskNo treatment given

Clinical Trials (5)

Total enrollment: 721 patients across 5 trials

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

Start: Aug 2017Est. completion: Jun 202036 patients
Phase 2Completed

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

Start: May 2008Est. completion: Jan 200991 patients
Phase 1Terminated

A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers

Start: Dec 2007Est. completion: Jan 200818 patients
Phase 1Completed

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

Start: Jan 2007Est. completion: Jul 2008127 patients
Phase 1Completed
NCT02568202Novo NordiskNo treatment given

Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)

Start: Sep 2015Est. completion: Nov 2015449 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.